• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aptiom (eslicarbazepine acetate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aptiom (eslicarbazepine acetate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown.

    Aptiom is specifically indicated as adjunctive treatment for partial-onset seizures.

    Aptiom is supplied as a tablet for oral administration. The recommended initial dose is 400 mg once daily. After one week, increase dosage to 800 mg once daily (recommended maintenance dosage). Maximum recommended maintenance dosage is 1200 mg once daily (after a minimum of one week at 800 mg once daily).

    Clinical Results

    FDA Approval
    The FDA approval of Aptiom was based on three randomized, double-blind, placebo-controlled, multicenter trials in adults with epilepsy (Studies 1, 2, and 3). Enrolled subjects had partial-onset seizures with or without secondary generalization and were not adequately controlled with 1 to 3 concomitant AEDs. Studies 1 and 2 compared dosages of Aptiom 400, 800, and 1200 mg once daily with placebo. Study 3 compared dosages of Aptiom 800 and 1200 mg once daily with placebo. In all three trials, following an 8­week Baseline Phase, which established a baseline seizure frequency, subjects were randomized to a treatment arm. The trials consisted of a treatment period consisting of an initial titration phase (2 weeks), and a subsequent maintenance phase (12 weeks). The specific titration schedule differed amongst the three studies. Thus, subjects were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved. The primary endpoint was the standardized seizure frequency during the Maintenance Phase over 28 days. The Aptiom treatment at 400 mg/day , in Studies 1 and 2, did not show significant treatment effect. A statistically significant effect was observed with Aptiom treatment at doses of 800 mg/day in Studies 1 and 2 but not in Study 3, and at doses of 1200 mg/day in all three studies.

    Side Effects

    Adverse effects associated with the use of Aptiom may include, but are not limited to, the following:

    • dizziness
    • somnolence
    • nausea,
    • headache
    • diplopia
    • vomiting
    • fatigue
    • vertigo
    • ataxia
    • blurred vision
    • tremor

    Mechanism of Action

    Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown.

    Literature References

    Elger C, Halász P, Maia J, Almeida L, Soares-da-Silva P; BIA-2093-301 Investigators Study Group Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009 Mar;50(3):454-63.

    Additional Information

    For additional information regarding Aptiom or partial onset seizures, please visit the Aptiom web page.

    Approval Date: 2013-11-01
    Company Name: Sunovion Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    • White House

      Trial Stakeholders Advise White House on Emergency Research Infrastructure

    • SurveywBlueBackground-360x240.png

      Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing